JR-AB2-011 |
Catalog No.GC34909 |
JR-AB2-011 est un inhibiteur sélectif de mTORC2 avec une valeur IC50 de 0,36 μM. JR-AB2-011 inhibe l'activité mTORC2 en bloquant l'association Rictor-mTOR (Ki : 0,19 μM). JR-AB2-011 possède des propriétés anti-glioblastome multiforme (GBM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2411853-34-2
Sample solution is provided at 25 µL, 10mM.
JR-AB2-011 is a selective mTORC2 inhibitor with an IC50 value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (Ki: 0.19 μM). JR-AB2-011 has anti-glioblastoma multiforme (GBM) properties[1]. mTORC2|0.36 μM (IC50)
JR-AB2-011 (1 μM; 24 hours) has good anti-GBM properties, blocks mTORC2 signaling and Rictor association with mTOR[1].JR-AB2-011 (0.5-2 μM; 48 hours) displays the least toxicity to normal neurons with no significant cytotoxic effects for concentrations up to 10 mM compared to CID613034[1]. Apoptosis Analysis[1] Cell Line: U87 GBM cells; LN229 GBM cells
Mice receiving JR-AB2-011 (4 mg/kg; daily i.p. for 10 days; 20 mg/kg; daily i.p. for 10 days) at either dosing regimen display marked inhibition of tumor growth rate (JR-AB2-011 at 4 mg/kg/d; 74% inhibition at end of dosing period; tumor growth delay 10.0 days; JR-AB2-011 at 20 mg/kg/d; 80% inhibition at end of dosing period; tumor growth delay 12.0 days) as compared to mice receiving vehicle alone[1]. Animal Model: LN229 cells in female C.B.-17-scid (Taconic) mice[1]
[1]. Benavides-Serrato A, et al. Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma. PLoS One. 2017 Apr 28;12(4):e0176599.
Average Rating: 5
(Based on Reviews and 14 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *